Background: The association between Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways and immunologic non-response among people living with HIV (PLHIV) on antiretroviral therapy (ART) is not well documented. This study aimed to characterize KEGG metabolic pathways among HIV-infected men who have sex with men (MSM) with different immunologic responses.
Methods: We recruited HIV-uninfected MSM (healthy controls, HC) and HIV-infected MSM on ART > 24 months in Guangzhou, June-October 2021. HIV-infected MSM with HIV viral load < 20 copies/mL were grouped into poor immunological responders (PIR) (CD4 + T cell count < 350 cells/µL) and good immunological responders (GIR) (CD4 + T cell count ≥ 350 cells/µL). Stool samples were collected. Bacterial 16S ribosomal DNA sequencing was performed on stool samples, and KEGG metabolic pathways of gut microbiota were imputed from 16S rDNA sequences.
Results: A total of 51 HC, 41 PIR, and 56 GIR were enrolled. The median time since HIV diagnosis for PIR and GIR was 4.6 and 4.2 years. KEGG metabolic pathways were significantly different among HC, PIR, and GIR groups. Retrograde endocannabinoid signaling, pantothenate and CoA biosynthesis, bile secretion, non-homologous end-joining, and gastric cancer were the top five important KEGG metabolic pathways associated with the immunologic responses. Specifically, retrograde endocannabinoid signaling performed best in discriminating PIR and GIR.
Conclusions: This study presented a comprehensive landscape of KEGG metabolic pathways in PLHIV with different treatment outcomes. These results suggest the potential of KEGG metabolic pathways as novel disease progression markers and therapeutic targets.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1186/s12879-025-10756-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda : A Cross-Sectional Study.
Ann Intern Med
March 2025
Massachusetts General Hospital, Boston, Massachusetts; Mbarara University of Science and Technology, Mbarara, Uganda; and Kabwohe Clinical Research Center, Kabwohe, Sheema, Uganda (S.A.).
Background: Data on the prevalence of coronary atherosclerotic disease (CAD) in the African region among people with and without HIV are lacking.
Objective: To estimate the prevalence of CAD in Uganda and determine whether well-controlled HIV infection is associated with increased presence or severity of CAD.
Design: Cross-sectional study.
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist.
J Immunol
February 2025
Gritstone Bio, Inc, Emeryville, CA, United States.
While therapeutic vaccines are a promising strategy for inducing human immunodeficiency virus (HIV) control, HIV vaccines tested to date have offered limited benefit to people living with HIV. The barriers to success may include the use of vaccine platforms and/or immunogens that drive weak or suboptimal immune responses, immune escape and/or immune dysfunction associated with chronic infection despite effective antiretroviral therapy. Combining vaccines with immune modulators in a safe manner may address some of the challenges and thus increase the efficacy of therapeutic HIV vaccines.
View Article and Find Full Text PDF[Association of systemic lupus and HIV/AIDS: nine observations at the Centre Hospitalier Universitaire de Libreville (Gabon)].
Med Trop Sante Int
December 2024
Service de médecine interne, CHU de Libreville, BP 2228, Libreville, Gabon.
Background: HIV/AIDS infection is endemic in sub-Saharan Africa. It is manifested by a variety of opportunistic diseases that usually occur when the CD4 count is below 200/mm, but also during the immune restoration syndrome (IRS) that occurs under highly active antiretroviral therapy (HAART). Autoimmune and inflammatory diseases are rarely associated with this condition.
View Article and Find Full Text PDFLongitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infection.
Front Immunol
March 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
Background: Trafficking of immune cells to the central nervous system is hypothesized to facilitate HIV entry and immune-induced neuronal injury and is mediated by surface proteins such as chemokine receptors and α4 integrin. We longitudinally assessed immune cell activation and surface marker expression in cerebrospinal fluid (CSF) and blood and their relationship with CSF HIV RNA beginning during primary HIV infection (PHI) before and after antiretroviral therapy (ART).
Methods: Longitudinal paired blood and CSF were obtained in ART-naïve PHI (<12 month since infection) participants; some independently initiated ART during follow up.
HIV controllers: hope for a functional cure.
Front Immunol
March 2025
Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Elite controllers (ECs) and post-treatment controllers (PTCs) represent important models for achieving a functional cure for HIV. This review synthesizes findings from immunological, genetic, and virological studies to compare the mechanisms underlying HIV suppression in ECs and PTCs. Although ECs maintain viral control without antiretroviral therapy (ART), PTCs achieve suppression following ART discontinuation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!